Pharma CEOs Face the U.S. Senate in Drug Price Hearings

The Finance Committee of the U.S. Senate held two hearings – one in January and one in February — on “Drug Pricing in America: A Prescription for Change.” As we’ve seen them unfold, they’ve been reminders of ongoing tensions with the industry, and a harbinger of what may be on the horizon for pharma manufacturers.